Abstract
Title: Circadian Timing of Immune Checkpoint Inhibitors and the Role of 8-OHdG as an Exploratory Repair-Flux Biomarker: A Scoping Review Protocol Purpose: This scoping review maps the breadth, type, and translational maturity of evidence at the intersection of circadian clock biology, DNA repair, tumor immunity, immune checkpoint inhibitor (ICI) timing, chronotype/phase personalization, and urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) as an exploratory biomarker. The review is guided by four questions: (1) What evidence links circadian clock biology with DNA repair and oxidative genome surveillance in cancer? (2) What mechanistic evidence connects clock disruption to tumor-immune microenvironment remodeling and time-dependent checkpoint activity? (3) What clinical evidence exists for time-of-day ICI administration across human cancers? (4) What is the translational status of chronotype/phase markers, tumor clock profiling, and urinary 8-OHdG for personalized chrono-immunotherapy? Background: Retrospective clinical cohorts have repeatedly shown that earlier time-of-day ICI administration is associated with improved survival across melanoma, NSCLC, ES-SCLC, mRCC, and head and neck cancer. The LungTIME-C01 randomized phase 3 trial (Huang et al., 2026, Nature Medicine) has now provided the first prospective confirmation, demonstrating that immunochemotherapy administered before 15:00 substantially improved progression-free survival (HR 0.40; P < 0.001) and overall survival in advanced NSCLC, with corroborating CD8+ T-cell immunophenotyping data. Despite this landmark result, biological phase was not measured in LungTIME-C01, timing definitions remain heterogeneous across studies, and no existing review has mapped this evidence alongside DNA repair biology, 8-OHdG biomarker science, and personalization strategies within a single integrative framework. Methods: The review follows PRISMA-ScR (Tricco et al., 2018) and JBI scoping review methodology (Peters et al., 2020; 2022). Four databases (PubMed/MEDLINE, Web of Science, Scopus, Cochrane Library) will be searched using four thematic waves covering chrono-immunotherapy, tumor-immune gating, DNA repair/8-OHdG, and personalization/clock modulation. Eligibility is operationalized through a PCC framework (Population: human and preclinical cancer studies; Concept: circadian clock, DNA repair, ICI timing, 8-OHdG; Context: solid tumor oncology). Sources will be charted against a standardized 16-field extraction framework. No formal risk-of-bias appraisal or meta-analysis is planned, consistent with the evidence-mapping objective. Expected outcomes: The review will produce: (a) a descriptive evidence landscape map characterizing the distribution and maturity of the mapped corpus; (b) thematic narrative syntheses across six domains (clock/repair biology, tumor-immune gating, clinical chrono-ICI evidence, personalization tools, 8-OHdG biomarker horizon, clock-modulating strategies); (c) an exploratory 8-OHdG-enabled personalized chrono-immunotherapy framework integrating host-phase screening, objective phase confirmation, tumor/regimen context, and longitudinal biomarker embedding; and (d) a research priorities agenda emphasizing multi-center replication of LungTIME-C01 with embedded biological-phase markers, standardized biomarker substudies, and operationally feasible scheduling algorithms. Key message: This review repositions urinary 8-OHdG from a static oxidative-damage marker to an exploratory, time-sensitive readout of oxidative damage/repair flux that may help operationalize personalized chrono-immunotherapy — while explicitly avoiding premature clinical overclaiming.